CIS vs. Relapsing-Remitting MS: What's the Difference?

Clinically isolated syndrome (CIS) is a person’s first neurological episode caused by inflammation and demyelination (damage to the protective covering of nerves) in the central nervous system, recognized only after other possible causes have been ruled out ^[1].

People often wonder how CIS differs from relapsing-remitting multiple sclerosis (RRMS). It helps to understand the difference between the initial event, the formal diagnosis, and the disease course:

Simply put, a person with CIS has had one attack. It becomes MS when objective evidence shows the disease is active over time and across different areas of the brain, spinal cord, or optic nerve ^[1]. Not everyone who experiences CIS will go on to meet the criteria for MS.

Ruling Out Other Conditions

A crucial part of diagnosing CIS or MS is ensuring there is “no better explanation” for your symptoms. Your neurologist will use blood tests, spinal fluid analysis, and MRI to rule out “mimics”—other conditions that can cause similar symptoms, such as neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody disease, severe vitamin deficiencies, infections, or even migraine-related changes ^[1][2].

How CIS Meets the Criteria for MS

Neurologists use a set of guidelines called the McDonald criteria (most recently updated in 2024) to determine if a person’s evidence meets the threshold for an MS diagnosis. A diagnosis requires two main elements ^[1]:

1. Dissemination in Space (DIS): Evidence that damage has occurred in multiple distinct areas. This is usually seen on an MRI as lesions (visible areas of change or damage) in at least two of five typical regions: near the brain’s fluid-filled spaces (periventricular), in the brain’s outer layers (cortical/juxtacortical), in the lower brain/brainstem (infratentorial), in the spinal cord, or in the optic nerve ^[3][4].
2. Dissemination in Time (DIT): Evidence that the damage has occurred at different points in time ^[1].

You do not necessarily have to wait for a second physical attack to be diagnosed with MS. Under the 2024 criteria, CIS can be reclassified as MS if DIS is established and any of the following occur:

• A second clinical attack (relapse): A true relapse is defined as new or clearly worsened neurological symptoms lasting at least 24 hours, occurring without a fever or infection, and separated from the first episode by at least a month ^[1]. (Temporary worsening of old symptoms during heat or illness is a “pseudo-relapse”).
• MRI changes: A follow-up MRI shows new lesions that were not there on the first scan ^[3].
• Simultaneous lesions: A single MRI shows both gadolinium-enhancing lesions (which absorb contrast dye, suggesting they are newer and actively inflamed) and non-enhancing lesions, suggesting the damage occurred at different times ^[5].
• Spinal fluid markers: A lumbar puncture (spinal tap) reveals CSF-restricted oligoclonal bands (OCBs) or an elevated kappa free-light-chain (κFLC) index ^[6][7]. These are immunoglobulin proteins indicating immune system activity. While they can occur in other inflammatory conditions, if they are found alongside a typical CIS presentation and a matching MRI, they can substitute for DIT without waiting for a new MRI lesion ^[8].

Risk Factors for an MS Diagnosis

If you have been diagnosed with CIS, the likelihood of it eventually meeting the criteria for MS varies based on several factors:

• MRI Lesion burden and location: Having multiple lesions on your baseline brain MRI increases the risk compared to having a normal or near-normal scan. Lesions located in the spinal cord or the brainstem/cerebellum are particularly strong predictors of future MS activity. A normal MRI lowers the risk, but does not eliminate it entirely ^[9][10].
• Spinal fluid findings: The presence of OCBs or an elevated κFLC index indicates a higher risk of future disease activity ^[11][10].
• Age: Younger age at the time of the first episode is associated with a greater risk of converting to MS ^[10].

Monitoring After a CIS Diagnosis

Because silent disease activity (new MRI lesions forming even if you feel completely fine) can occur, careful monitoring is essential.

• Individualized schedules: Your neurologist will recommend a monitoring timeline based on your baseline MRI, symptoms, and age. A common approach involves clinical exams and a repeat MRI at 3 to 6 months, and then annually, but this is highly personalized ^[12][11].
• Spinal cord imaging: It is important that follow-up includes spinal cord imaging when clinically appropriate, as spinal cord lesions can appear without new brain lesions ^[13].

When is Treatment Discussed?

Treatment discussions for CIS usually fall into two categories:

1. Treating the acute episode: If your first attack causes severe, function-limiting symptoms, your doctor may prescribe a short course of high-dose corticosteroids. This helps speed up recovery from the acute attack, but steroids do not prevent future MS activity or replace long-term therapies.

2. Long-term prevention: Disease-modifying therapies (DMTs) are medications designed to calm the immune system and reduce the risk of relapses and new MRI lesions.

• For a person with “high-risk” CIS—such as someone with multiple MRI lesions, spinal cord involvement, or positive spinal fluid markers—neurologists often recommend starting a DMT. Clinical trials have shown that certain DMTs can reduce the risk of relapses and delay the time it takes to meet the criteria for clinically definite MS ^[14][15].
• However, DMTs differ substantially in their mechanisms, side effects, monitoring requirements, and pregnancy implications. Because of this, individuals with a lower-risk CIS profile may choose, alongside their doctor, to take a “wait and see” approach with close MRI monitoring instead ^[16][17].

This is always a shared decision-making process, balancing the potential medication side effects against the likelihood of developing MS.